Αρχική World News FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy... World News FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine Therapy for the Maintenance Treatment of HR-positive, HER2-positive LA/MBC Από Ogkologos - 29 Ιουλίου, 2026 194 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PATINA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Combination Therapy for Metastatic Prostate Cancer Helps Some Men Live Longer 11 Μαρτίου, 2025 Mom Says Family Was Kicked Out Of Movie Theater Because Her... 19 Απριλίου, 2019 Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence... 4 Απριλίου, 2024 Why investing in cancer research is good for the economy 1 Ιουλίου, 2022 Φόρτωση περισσοτέρων HOT NEWS How People With Advanced Cancer Can Find Meaning Toward the End... ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung... Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma Second Interim Analysis Shows OS Improvement with Adjuvant Olaparib for Germline...